Literature DB >> 23102808

Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.

Amir Abdolahi1, Nicholas Scoglio, Annie Killoran, E Ray Dorsey, Kevin M Biglan.   

Abstract

BACKGROUND: By permitting remote assessments of patients and research participants, telemedicine has the potential to reshape clinical care and clinical trials for Parkinson disease. While the majority of the motor Unified Parkinson's Disease Rating Scale (UPDRS) items can be conducted visually, rigidity and retropulsion pull testing require hands-on assessment by the rater and are less feasible to perform remotely in patients' homes.
METHODS: In a secondary data analysis of the Comparison of the Agonist pramipexole vs. Levodopa on Motor complications in Parkinson's Disease (CALM-PD) study, a randomized clinical trial, we assessed the cross-sectional (baseline and 2 years) and longitudinal (change from baseline to 2 years) reliability of a modified motor UPDRS (removing rigidity and retropulsion items) compared to the standard motor UPDRS (all items) using intraclass correlation coefficients (ICC), stratified by treatment group. Internal consistency of the modified UPDRS (mUPDRS) was measured using Cronbach's alpha, and concurrent validity was assessed using Pearson's correlation coefficient (r) between the standard motor UPDRS and mUPDRS.
RESULTS: The mUPDRS versus standard motor UPDRS is cross-sectionally (ICC ≥ 0.92) and longitudinally (ICC ≥ 0.92) reliable for both treatment groups. High internal consistencies were also observed (α ≥ 0.96). The mUPDRS had high concurrent validity with the standard UPDRS at both time points and longitudinally (r ≥ 0.93, p < 0.0001).
CONCLUSIONS: A modified version of the motor UPDRS without rigidity and retropulsion pull testing is reliable and valid and may lay the foundation for its use in remote assessments of patients and research participants.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102808      PMCID: PMC3666325          DOI: 10.1016/j.parkreldis.2012.10.008

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease.

Authors:  E Ray Dorsey; Lisa M Deuel; Tiffini S Voss; Kara Finnigan; Benjamin P George; Sheelah Eason; David Miller; Jason I Reminick; Anna Appler; Joyce Polanowicz; Lucy Viti; Sandy Smith; Anthony Joseph; Kevin M Biglan
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

2.  Responsiveness of impairments and disabilities in Parkinson's disease.

Authors:  M Visser; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  Parkinsonism Relat Disord       Date:  2006-04-18       Impact factor: 4.891

Review 3.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

4.  Predictors of future falls in Parkinson disease.

Authors:  G K Kerr; C J Worringham; M H Cole; P F Lacherez; J M Wood; P A Silburn
Journal:  Neurology       Date:  2010-06-23       Impact factor: 9.910

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

6.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

7.  Telemedicine for the care of nursing home residents with Parkinson's disease.

Authors:  Kevin M Biglan; Tiffini S Voss; Lisa M Deuel; David Miller; Sheelah Eason; Maria Fagnano; Benjamin P George; Anna Appler; Joyce Polanowicz; Lucy Viti; Sandy Smith; Anthony Joseph; E Ray Dorsey
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

8.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Authors:  Robert G Holloway; Ira Shoulson; Stanley Fahn; Karl Kieburtz; Anthony Lang; Kenneth Marek; Michael McDermott; John Seibyl; William Weiner; Bruno Musch; Cornelia Kamp; Mickie Welsh; Aileen Shinaman; Rajesh Pahwa; Lynn Barclay; Jean Hubble; Peter LeWitt; Janis Miyasaki; Oksana Suchowersky; Mark Stacy; David S Russell; Blair Ford; John Hammerstad; David Riley; David Standaert; Frederick Wooten; Stewart Factor; Joseph Jankovic; Farah Atassi; Roger Kurlan; Michel Panisset; Ali Rajput; Robert Rodnitzky; Cliff Shults; Giselle Petsinger; Cheryl Waters; Ronald Pfeiffer; Kevin Biglan; Leona Borchert; Amy Montgomery; Laura Sutherland; Carolyn Weeks; Maryan DeAngelis; Elspeth Sime; Susan Wood; Carol Pantella; Mary Harrigan; Barbara Fussell; Sandra Dillon; Barbara Alexander-Brown; Pamela Rainey; Marsha Tennis; Elke Rost-Ruffner; Diane Brown; Sharon Evans; Debra Berry; Jean Hall; Theresa Shirley; Judith Dobson; Deborah Fontaine; Brenda Pfeiffer; Alicia Brocht; Susan Bennett; Susan Daigneault; Karen Hodgeman; Carolynn O'Connell; Tori Ross; Karen Richard; Arthur Watts
Journal:  Arch Neurol       Date:  2004-07

9.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Authors:  R Katzenschlager; J Head; A Schrag; Y Ben-Shlomo; A Evans; A J Lees
Journal:  Neurology       Date:  2008-06-25       Impact factor: 9.910

10.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

View more
  40 in total

Review 1.  The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach.

Authors:  H Ben-Pazi; P Browne; P Chan; E Cubo; M Guttman; A Hassan; J Hatcher-Martin; Z Mari; E Moukheiber; N U Okubadejo; A Shalash
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-13       Impact factor: 5.081

2.  Interdisciplinary palliative care for people with advanced Parkinson's disease: a view from the home.

Authors:  Jori E Fleisher; Ellen C Klostermann; Serena P Hess; Jeanette Lee; Erica Myrick; Joshua Chodosh
Journal:  Ann Palliat Med       Date:  2019-10-14

Review 3.  The Phenomenology of Parkinson's Disease.

Authors:  Christopher W Hess; Mark Hallett
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

4.  Randomized controlled clinical trial of "virtual house calls" for Parkinson disease.

Authors:  E Ray Dorsey; Vinayak Venkataraman; Matthew J Grana; Michael T Bull; Benjamin P George; Cynthia M Boyd; Christopher A Beck; Balaraman Rajan; Abraham Seidmann; Kevin M Biglan
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

5.  High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study.

Authors:  Jayne R Wilkinson; Meredith Spindler; Stephanie M Wood; Steven C Marcus; Daniel Weintraub; James F Morley; Margaret G Stineman; John E Duda
Journal:  Neurol Clin Pract       Date:  2016-06

6.  Feasibility of Virtual Research Visits in Fox Trial Finder.

Authors:  E Ray Dorsey; Joseph D Wagner; Michael T Bull; Ashley Rizzieri; Justin Grischkan; Meredith A Achey; Todd Sherer; Sohini Chowdhury; Claire Meunier; Lily Cappelletti; Charlotte Rocker; Irene H Richard; Heidi Schwarz; Gail Kang; Stacy H Ahmad; Rachel A Biemiller; Kevin M Biglan
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 7.  [Remote assessment of idiopathic Parkinson's disease : Developments in diagnostics, monitoring and treatment].

Authors:  U Kleinholdermann; J Melsbach; D J Pedrosa
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

8.  Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease.

Authors:  Baijayanta Maiti; Jonathan M Koller; Abraham Z Snyder; Aaron B Tanenbaum; Scott A Norris; Meghan C Campbell; Joel S Perlmutter
Journal:  Neurology       Date:  2019-12-17       Impact factor: 9.910

9.  National randomized controlled trial of virtual house calls for Parkinson disease.

Authors:  Christopher A Beck; Denise B Beran; Kevin M Biglan; Cynthia M Boyd; E Ray Dorsey; Peter N Schmidt; Richard Simone; Allison W Willis; Nicholas B Galifianakis; Maya Katz; Caroline M Tanner; Kristen Dodenhoff; Jason Aldred; Julie Carter; Andrew Fraser; Joohi Jimenez-Shahed; Christine Hunter; Meredith Spindler; Suzanne Reichwein; Zoltan Mari; Becky Dunlop; John C Morgan; Dedi McLane; Patrick Hickey; Lisa Gauger; Irene Hegeman Richard; Nicte I Mejia; Grace Bwala; Martha Nance; Ludy C Shih; Carlos Singer; Silvia Vargas-Parra; Cindy Zadikoff; Natalia Okon; Andrew Feigin; Jean Ayan; Christina Vaughan; Rajesh Pahwa; Rohit Dhall; Anhar Hassan; Steven DeMello; Sara S Riggare; Paul Wicks; Meredith A Achey; Molly J Elson; Steven Goldenthal; H Tait Keenan; Ryan Korn; Heidi Schwarz; Saloni Sharma; E Anna Stevenson; William Zhu
Journal:  Neurology       Date:  2017-08-16       Impact factor: 9.910

10.  24/7 Live Stream Telemedicine Home Treatment Service for Parkinson's Disease Patients.

Authors:  Gregor Durner; Joachim Durner; Henrike Dunsche; Etzel Walle; Robert Kurzreuther; René Handschu
Journal:  Mov Disord Clin Pract       Date:  2016-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.